Press release

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on

articleKalvista Pharmaceuticals, Inc.April 3, 20243/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-to-present-at-23rd-annual-needham-virtual-healthcare
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

About this update from Kalvista Pharmaceuticals, Inc.

[{"type":"text","content":" CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 10:15 a.m. ET.\n\n\nA live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.\n\n\nAbout KalVista Pharmaceuticals, Inc.\n\n\nKalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. Food and Drug Administration (FDA)for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.\n\n\nFor more information about KalVista, please visit www.kalvista.com.\n\n\nForward-Looking Statements\n\n\nThis press release contains \"forward-looking\" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: \"anticipate,\" \"intend,\" \"plan,\" \"goal,\" \"seek,\" \"believe,\" \"project,\" \"estimate,\" \"expect,\" \"strategy,\" \"future,\" \"likely,\" \"may,\" \"should,\" \"will\" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates, our ability to obtain regulatory approvals for sebetralstat and other candidat...

More updates from Kalvista Pharmaceuticals, Inc.